Cancer Biomarkers; Biological Molecules That Suggest the Presence of Cancer in the Patient
A biomarker refers to a substance or process that is indicative of the presence of cancer in the body. Cancer Biomarkers are biomolecules produced either by the tumor cells or by other cells of the body in response to the tumor.
Biomarkers are widely used to detect and manage cancer patients. In patients who have had palliative surgery for cancer, these biomarkers are used for follow-up monitoring and early detection of potentially recurrent disease. Moreover, they can be used as a part of routine diagnostic tests.
Cancer Biomarkers are tools used to detect the disease process and monitor the response to therapy in cancer patients. A biomarker refers to any substance or procedure that is characteristic of the existence of cancer in the human body.
A biomarker can be a substance secreted by the tumor itself or a general biological response of the body to the existence of cancer. It is a biological molecule produced by the body or tumor in a person with cancer. Biomarker found in blood, urine, or body tissues can be elevated by the presence of one or more types of cancer.
The Cancer Biomarkers Market is anticipated to reach US$ 21,643.9 million in 2022 and grow at a CAGR of 14.4% during the following five years (2022-2030).
Furthermore, several governments across the world are increasingly investing in cancer prevention and early intervention to reduce the physical/emotional impact of cancer on patients and their families.
Many Cancer Biomarkers currently being tested in clinical trials to assess their activity on various cancers. Although these tests are still at an early stage, many exciting results are being seen with each passing day. Moreover, continued advances in cancer diagnosis include the use of molecular biomarkers as part of routine clinical trials.
Healthcare departments are also focusing on developing safe and effective cancer treatments. For instance, in November 2019, Hitachi and Centre Léon Bérard Cancer Center in France promoted R&D aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab.

Comments
Post a Comment